A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice

**Dear Editor,**

Since the beginning of this century, humanity has been struck three times by the coronavirus outbreak. The most recent one is caused by the SARS-CoV-2 virus, which was first reported in January 2020 and spread rapidly worldwide, developing into a global coronavirus disease pandemic coded COVID-19. By July 28, 2020, SARS-CoV-2 has caused over sixteen million COVID-19 cases worldwide and 650,805 deaths. Such a grave situation has made the development of a COVID-19 vaccine imperative and urgent.

In this study, we designed three mRNA vaccine candidates for COVID-19, and they encode various forms of antigens in vaccinated hosts (Fig. 1a). RQ3011-RBD encodes the receptor-binding domain of the S (spike) glycoprotein (residues 331–524) of SARS-CoV-2 with an N-terminal signal peptide and a C-terminal membrane-anchoring helix. Vaccine RQ3013-Spike encodes the full-length wild-type S, while RQ3013-VLP is formulated from a cocktail of mRNAs encoding three structural proteins: S, M (membrane), and E (envelope) to form SARS-CoV-2 virus-like particles (VLPs). To increase the expression capacity of mRNA vaccines, all mRNAs were subjected to an in-depth sequence optimization procedure of two parameters: codons in the DNA template and modified nucleotides incorporated into mRNA. We designed ten coding sequences of the S gene (3822 nucleotides in length) with varying GC-content, maintaining the maximum codon adaptation index. For each DNA template, we tested six mRNA species with various modified nucleotides. The mRNA candidates (total of 60) displayed a considerable variation in their abilities to express S in HEK 293A cells (Supplementary information, Fig. S1a). Notably, the incorporation of pseudouridine consistently improves the expression of S, regardless of the codon sequence used. For M and E, which are relatively small proteins, we designed one codon-optimized sequence for the codon sequence used. For M and E, which are relatively small proteins, we designed one codon-optimized sequence for the codon sequence used. For M and E, which are relatively small proteins, we designed one codon-optimized sequence for the codon sequence used.

All sera were evaluated for binding to the S ectodomain by enzyme-linked immunosorbent assay (ELISA). Binding antibodies can be detected in mice immunized with RQ3012-Spike and RQ3013-VLP on days 20 after the first injection, while RQ3011-RBD showed marginal stimulation (Fig. 1f). Following a boost, the antibody titers increased dramatically in mice receiving RQ3012-Spike or RQ3013-VLP, and peaked at week 3, remaining stable at week 8. A boost did not increase the titer for RQ3011-RBD, which dropped to the level of the placebo group. Notably, mice receiving RQ3013-VLP had the strongest immune response and developed significantly higher titers of S-specific binding antibody than mice receiving RQ3012-Spike.

Since we included M and E mRNA in RQ3013-VLP, we analyzed whether M and E induced protein-specific immunoglobulin G (IgG). For that purpose, sub-VLPs consisting of M and E proteins were purified and used for ELISA. No M- or E-specific antibodies were detected in mice vaccinated with RQ3013-VLP (Supplementary information, Fig. S2c).

The presence of neutralizing antibodies (NAbS) was evaluated for all groups using our recently established pseudovirus neutralization assay for SARS-CoV-2. We and others have previously demonstrated that NAB titers measured from the vesicular stomatitis virus (VSV) pseudovirus assay correlated well with NAB titers measured from a live SARS-CoV-2 virus assay. In mice receiving RQ3012-Spike, the mean NAB titers (EC50) reached 10,000 at week 4, 1 week after a boost, and peaked at week 6, maintaining relatively stable at week 8 (Fig. 1g and Supplementary information, Fig. S2a, b). In mice receiving RQ3013-VLP, the mean NAB titer rose to 25,028 at week 4, 2.5-fold higher than that in the RQ3012-Spike group. By week 8, the NAB titer was still increasing, with the highest EC50 value of more than 100,000. The differences in NAB titers between RQ3012-Spike and RQ3013-VLP are significantly higher than those in the RQ3012-Spike group.

**Received: 8 June 2020 Accepted: 29 July 2020**

**SPRINGER NATURE © The Author(s) 2020**
the exception of one animal, there are no detectable NAbS in mice receiving RQ3011-RBD.

T cell response is critical for vaccine-induced cellular and humoral protection against future infection. Mice immunized with RQ3013-VLP showed altered CD4⁺:CD8⁺ T cell ratio (0.67:0.29) in the blood compared to the placebo group (0.74:0.20), with a significant increase in CD8⁺ T cell frequency, which is important for antiviral immunity (Fig. 1h). Both RQ3012-Spike and RQ3013-VLP induced comparable CD4⁺ T cell activation, while RQ3012-Spike induced slightly higher CD8⁺ T cell activation, as demonstrated by CD44 staining (Fig. 1j). However, higher CD8⁺ T cell activation in RQ3012-Spike immunized mice may not be necessarily specific to the antigen used in vaccination, as vaccines can induce numerous immune factors, such as cytokines, to influence bystander activations of CD8⁺ T cells. To assess the vaccine-specific T cell activation, peripheral blood mononuclear cells (PBMCs) from
Humoral and cellular immune responses of COVID-19 mRNA LNP vaccine candidates. a The three mRNA vaccine candidates for COVID-19. RQ3011-RBD contains an mRNA encoding the receptor binding domain of S with a C-terminal membrane-anchoring helix. RQ3012-Spike contains an mRNA encoding the full-length wild-type (WT) S. RQ3013-LNP contains three mRNAs encoding S, M, and E proteins that can assemble into VLPs. b Electron microscopy images of VLPs produced by RQ3013-VLP. VLPs in the cell culture supernatant were purified and concentrated by ultracentrifugation and subjected to negative staining for electron microscopy. Scale bar, 500 nm. c The expression of S with various glycans. GC-content for each sequence is indicated in the parenthesis. All S mRNAs have uridine replaced by Ψ. d Screening for optimal modified nucleotides in M and E mRNAs. A codon-optimized sequence for each gene was tested for protein expression with six different kinds of modified nucleotides. They are uridine (lane 1), m7Gm(CΨ) (lane 2), Ψ (lane 3), m0Ψ (lane 4), m1Ψ (lane 5), and m0C (lane 6). All mRNAs were used to transfet HEK 293A cells, and protein expression was detected by western blotting. EGFp mRNA was used as a negative control. The mRNAs used in vaccines are indicated by stars. e The scheme of mice immunization. Mice (n = 10 per group) were either mock-immunized with Placebo (empty LNP, blue circle) or vaccinated with RQ3011-RBD (red square), RQ3012-Spike (green triangle), and RQ3013-VLP (purple diamonds) intramuscularly. Time points of vaccination and bleeding are indicated by arrows. f The antibody response was analyzed by ELISA using the S antigen. The black dashed line indicates the titer of pre-immune mice (n = 10). g Neutralizing antibodies were analyzed by the VSV-based pseudovirus assay. Lines represent average titers of all animals in each vaccine group. The black dashed line indicates the limit of detection of the assay (reciprocal titer of 100). Any measurement below the limit of detection was assigned a value of half the limit of detection for plotting and statistical purposes. h Frequency changes of CD4⁺ and CD8⁺ T cells 8 weeks after vaccination. The RQ3011-RBD group was omitted for analysis. The significance of the ratio difference was indicated. i Frequency of CD4⁺CD8⁻/CD4⁺ and CD4⁺CD8⁻/CD8⁺ T effector cells 8 weeks after vaccination. j, k Antigen-specific responses were assessed by in vitro antigen restimulation. PBMCs isolated from the blood were stimulated with either SARS-CoV-2 VLPs or S protein and analyzed via flow cytometry for the frequency of VLP or Spike-specific CD4⁺ and CD8⁺ T cells expressing IFN-γ. Statistical analyses were carried out by Student’s t test when two groups were analyzed, and by ANOVA when more than two groups were analyzed (**P < 0.005; ***P < 0.001; ****P < 0.0001).

AUTHOR CONTRIBUTIONS
J.Lin, Y.X., H.Y., N.X., and T.Z. conceived and designed the experiments. J. Lu, G.L., S.T., J.X., H.X., X.F.Y., Q.Q., X.Y., and L.L. participated in multiple experiments; J. Lu, G.L., X.F. Y., N.X., T.Z., Y.X., and J. Lin analyzed the data. J. Lin and Y.X. wrote the manuscript. All authors provided the final approval of the manuscript.

ADDITIONAL INFORMATION
Supplementary information accompanies this paper at https://doi.org/10.1038/s41422-020-00392-7.

Competing interests: The authors declare no competing interests.

ACKNOWLEDGEMENTS
This work was supported by the Fudan University Special Funds for COVID-19 and the Shanghai Municipal Science and Technology Major Project (20175H2DZX01) to J. Lin, Shanghai Jiao Tong University Special Funds for COVID-19 to Y.X., the National Natural Science Foundation of China (81991495) to T.Z., and the Shanghai RNA Cure Biopharma. We thank Dr. Wei Yu, Dr. Jin Li, Dr. Shangyu Hong, and Dr. Jiaxue Wu for assistance in animal experiments. We also thank Dr. Xi Zhu for assistance in LNP formulations, and Professors Li Jin and Xinhua Lin for reading our manuscript and providing insightful suggestions.
REFERENCES
1. Zhu, N. et al. *N. Engl. J. Med.* **382**, 727–733 (2020).
2. WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (2020).
3. Amanat, F. & Krammer, F. *Immunity* **52**, 583–589 (2020).
4. Nakauchi, M. et al. *Microbiol. Immunol.* **52**, 625–630 (2008).
5. Wang, C. et al. *Oncotarget* **8**, 12686–12694 (2017).
6. Xia, J. et al. *ChinaXiv* https://www.chinaxiv.org/abs/202002.00070v1 (2020).
7. Siu, Y. L. et al. *J. Virol.* **82**, 11318–11330 (2008).
8. Xiong, H.-L. et al. *bioRxiv* https://doi.org/10.1101/2020.04.08.026948 (2020).
9. Nie, J. et al. *Emerg. Microbes Infect.* **9**, 680–686 (2020).
10. Chroboczek, J., Szurgot, I. & Szolajska, E. *Acta Biochim. Pol.* **61**, 531–539 (2014).
11. Yu, J. et al. *Science* https://doi.org/10.1126/science.abc6284 (2020).